Deng Han, Zhou Junxiang, Liu Zhixi, Huang Lu, Gu Yanru, Chen Peng, Xiao Hongtao
Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, No. 55, Section 4, South Renmin Road, Chengdu, Sichuan, China.
Med Oncol. 2025 Jan 7;42(2):40. doi: 10.1007/s12032-024-02591-3.
In the past decade, a variety of immune checkpoint inhibitors (ICIs) are currently approved for lung cancer in the world. As a new therapeutic approach, ICIs have shown significant clinical benefits in the first-line or second-line treatment for advanced lung cancer, improving the survival and quality of life of patients. Patients need to take multiple drugs in the meantime due to their own disease or side effects during treatment. In view of drug interactions, concomitant medications have a positive or negative impact on the prognosis of lung cancer patients. In this review, we reviewed the effects of multiple drugs on the prognosis of patients with lung cancer taking ICIs. Several studies indicate that antibiotics, proton pump inhibitors (PPIs), corticosteroids, and opioid analgesics can decrease the efficacy of ICIs. Aspirin and bone-targeting drugs can enhance the efficacy of ICIs and improve the survival rate. The effects of metformin (MET), renin-angiotensin-aldosterone system inhibitors (RASI), nonsteroidal anti-inflammatory drug (NSAIDS) (except aspirin), and statins on ICIs are controversial. Future research should further explore the effects of these concomitant medications on ICIs and develop personalized prescriptions based on the specific needs of patients.
在过去十年中，多种免疫检查点抑制剂（ICI）目前已在全球获批用于肺癌治疗。作为一种新的治疗方法，ICI在晚期肺癌的一线或二线治疗中已显示出显著的临床益处，提高了患者的生存率和生活质量。由于患者自身疾病或治疗期间的副作用，患者需要同时服用多种药物。鉴于药物相互作用，合并用药对肺癌患者的预后有积极或消极影响。在本综述中，我们回顾了多种药物对接受ICI治疗的肺癌患者预后的影响。多项研究表明，抗生素、质子泵抑制剂（PPI）、皮质类固醇和阿片类镇痛药会降低ICI的疗效。阿司匹林和骨靶向药物可增强ICI的疗效并提高生存率。二甲双胍（MET）、肾素-血管紧张素-醛固酮系统抑制剂（RASI）、非甾体抗炎药（NSAIDS，阿司匹林除外）和他汀类药物对ICI的影响存在争议。未来的研究应进一步探索这些合并用药对ICI的影响，并根据患者的具体需求制定个性化处方。
